{
    "text_blocks": {
        "data": {
            "block_count": 1,
            "table_index": 0
        },
        "model": null,
        "timestamp": "2025-01-21_09-31-44"
    },
    "table_comments": {
        "data": "CONSOLIDATED BALANCE SHEETS\tDollars in Millions, Except Share and Per Share Data\tDecember 31,\t",
        "timestamp": "2025-03-11_12-13-41"
    },
    "units": {
        "data": {
            "sum_units": 1000000,
            "sum_divider": 1.0
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "1000000",
                    "1": "1000000"
                },
                "decision": "1000000"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-13-45"
    },
    "post_table_text": {
        "data": "\tThe accompanying notes are an integral part of these consolidated financial statements.\t56\tBRISTOL-MY",
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "'\tThe accompanying notes are an integral part of these consolidated financial statements.\t56\tBRISTOL-MY'"
                },
                "decision": "'\tThe accompanying notes are an integral part of these consolidated financial statements.\t56\tBRISTOL-MY'"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-13-46"
    },
    "table_body": {
        "data": "ASSETS\t2018\t2017\tCurrent Assets:\tCash and cash equivalents\t$\t6,911\t$\t5,421\tMarketable securities\t1,973\t1,391\tReceivables\t5,965\t6,300\tInventories\t1,195\t1,166\tPrepaid expenses and other\t1,116\t576\tTotal Current Assets\t17,160\t14,854\tProperty, plant and equipment\t5,027\t5,001\tGoodwill\t6,538\t6,863\tOther intangible assets\t1,091\t1,210\tDeferred income taxes\t1,371\t1,610\tMarketable securities\t1,775\t2,480\tOther assets\t2,024\t1,533\tTotal Assets\t$\t34,986\t$\t33,551\tLIABILITIES\tCurrent Liabilities:\tShort-term debt obligations\t$\t1,703\t$\t987\tAccounts payable\t1,892\t2,248\tAccrued liabilities\t6,489\t6,014\tDeferred income\t172\t83\tIncome taxes payable\t398\t231\tTotal Current Liabilities\t10,654\t9,563\tDeferred income\t468\t454\tIncome taxes payable\t3,043\t3,548\tPension and other liabilities\t1,048\t1,164\tLong-term debt\t5,646\t6,975\tTotal Liabilities\t20,859\t21,704\tCommitments and contingencies\tEQUITY\tBristol-Myers Squibb Company Shareholders  Equity:\tPreferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,590 in 2018 and 4,070 in 2017, liquidation value of $50 per share\t \t \tCommon stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2018 and 2017\t221\t221\tCapital in excess of par value of stock\t2,081\t1,898\tAccumulated other comprehensive loss\t(2,762\t)\t(2,289\t)\tRetained earnings\t34,065\t31,160\tLess cost of treasury stock   576 million common shares in 2018 and 575 million common shares in 2017\t(19,574\t)\t(19,249\t)\tTotal Bristol-Myers Squibb Company Shareholders' Equity\t14,031\t11,741\tNoncontrolling interest\t96\t106\tTotal Equity\t14,127\t11,847\tTotal Liabilities and Equity\t$\t34,986\t$\t33,551",
        "timestamp": "2025-03-11_12-13-46"
    },
    "table_json_created": {
        "data": true,
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "{\"ASSETS\": {\"Current Assets\": {\"Cash and cash equivalents\": [6911, 5421], \"Marketable securities\": [1973, 1391], \"Receivables\": [5965, 6300], \"Inventories\": [1195, 1166], \"Prepaid expenses and other\": [1116, 576], \"Total Current Assets\": [17160, 14854]}, \"Property, plant and equipment\": [5027, 5001], \"Goodwill\": [6538, 6863], \"Other intangible assets\": [1091, 1210], \"Deferred income taxes\": [1371, 1610], \"Marketable securities\": [1775, 2480], \"Other assets\": [2024, 1533], \"Total Assets\": [34986, 33551]}, \"LIABILITIES\": {\"Current Liabilities\": {\"Short-term debt obligations\": [1703, 987], \"Accounts payable\": [1892, 2248], \"Accrued liabilities\": [6489, 6014], \"Deferred income\": [172, 83], \"Income taxes payable\": [398, 231], \"Total Current Liabilities\": [10654, 9563]}, \"Deferred income\": [468, 454], \"Income taxes payable\": [3043, 3548], \"Pension and other liabilities\": [1048, 1164], \"Long-term debt\": [5646, 6975], \"Total Liabilities\": [20859, 21704], \"Commitments and contingencies\": null}, \"EQUITY\": {\"Bristol-Myers Squibb Company Shareholders Equity\": {\"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,590 in 2018 and 4,070 in 2017, liquidation value of $50 per share\": null, \"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2018 and 2017\": [221, 221], \"Capital in excess of par value of stock\": [2081, 1898], \"Accumulated other comprehensive loss\": [-2762, -2289], \"Retained earnings\": [34065, 31160], \"Less cost of treasury stock 576 million common shares in 2018 and 575 million common shares in 2017\": [-19574, -19249], \"Total Bristol-Myers Squibb Company Shareholders' Equity\": [14031, 11741]}, \"Noncontrolling interest\": [96, 106], \"Total Equity\": [14127, 11847]}, \"Total Liabilities and Equity\": [34986, 33551]}"
                },
                "decision": "{\"ASSETS\": {\"Current Assets\": {\"Cash and cash equivalents\": [6911, 5421], \"Marketable securities\": [1973, 1391], \"Receivables\": [5965, 6300], \"Inventories\": [1195, 1166], \"Prepaid expenses and other\": [1116, 576], \"Total Current Assets\": [17160, 14854]}, \"Property, plant and equipment\": [5027, 5001], \"Goodwill\": [6538, 6863], \"Other intangible assets\": [1091, 1210], \"Deferred income taxes\": [1371, 1610], \"Marketable securities\": [1775, 2480], \"Other assets\": [2024, 1533], \"Total Assets\": [34986, 33551]}, \"LIABILITIES\": {\"Current Liabilities\": {\"Short-term debt obligations\": [1703, 987], \"Accounts payable\": [1892, 2248], \"Accrued liabilities\": [6489, 6014], \"Deferred income\": [172, 83], \"Income taxes payable\": [398, 231], \"Total Current Liabilities\": [10654, 9563]}, \"Deferred income\": [468, 454], \"Income taxes payable\": [3043, 3548], \"Pension and other liabilities\": [1048, 1164], \"Long-term debt\": [5646, 6975], \"Total Liabilities\": [20859, 21704], \"Commitments and contingencies\": null}, \"EQUITY\": {\"Bristol-Myers Squibb Company Shareholders Equity\": {\"Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,590 in 2018 and 4,070 in 2017, liquidation value of $50 per share\": null, \"Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2018 and 2017\": [221, 221], \"Capital in excess of par value of stock\": [2081, 1898], \"Accumulated other comprehensive loss\": [-2762, -2289], \"Retained earnings\": [34065, 31160], \"Less cost of treasury stock 576 million common shares in 2018 and 575 million common shares in 2017\": [-19574, -19249], \"Total Bristol-Myers Squibb Company Shareholders' Equity\": [14031, 11741]}, \"Noncontrolling interest\": [96, 106], \"Total Equity\": [14127, 11847]}, \"Total Liabilities and Equity\": [34986, 33551]}"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-12_11-21-32"
    },
    "problems": {
        "data": [],
        "timestamp": "2025-03-12_11-21-32"
    }
}